Hoechst long-term diltiazem use trial planned; CCB labeling should warn of mortality risk -- HRG petition.
Executive Summary
DILTIAZEM LARGE-SCALE TRIAL TO ADDRESS CCB CONCERNS about an association between calcium channel blocker use and increased risk of cardiovascular events. In a lead-up announcement to the American Heart Association annual meeting Nov. 13-16 in Anaheim. Hoechst Marion Roussel states that it will conduct a three-year prospective study of Cardizem CD, with the intention of finding "definitive answers about the long-term effects of Cardizem CD in treating high blood pressure."